VEGFA and endophthalmitis: Large-scale studies have reported the frequency of infectious endophthalmitis associated with original anti-VEGF agents as an adverse event to be between 0.02% and 0.14%, while the incidence of sterile endophthalmitis after intravitreal anti-VEGF therapy ranges from 0.005% to 4.4% [3].